ESMO 2018 Kidney Cancer

Viewing 1-20 of 23 articles

ESMO 2018: Can Biology Help Guide Treatment Decisions in Renal Cancer?

ESMO 2018: Challenging Established Frontline Therapies in Renal Cancer

ESMO 2018: PRINCIPAL Study - Real-World Effectiveness of Pazopanib in Patients with Intermediate Prognostic Risk Advanced Renal Cell Carcinoma

ESMO 2018: Safety and Tolerability of Atezolizumab plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma: IMmotion 150 and IMmotion 151

ESMO 2018: KEYNOTE-427 Cohort A: Pembrolizumab Monotherapy as First-line Therapy in advanced clear cell Renal Cell Carcinoma (ccRCC)

ESMO 2018: Activity of Cabozantinib After PD-1/PD-L1 Immune Checkpoint Blockade In Metastatic Clear Cell Renal Cell Carcinoma

ESMO 2018: COSMIC-021, Phase Ib Study of Cabozantinib in Combination with Atezolizumab and Potent Natural Killer, Myeloid Blood Cell Remodeling by Cabozantinib

ESMO 2018: Avelumab + Axitinib vs Sunitinib for the Management of Advanced Renal Cell Carcinoma - JAVELIN Renal 101

ESMO 2018: JAVELIN Renal 101: A Randomized, Phase 3 Study of Avelumab + Axitinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma

ESMO 2018: Efficacy and Safety Results of GETUG, Axitinib in Metastatic Papillary Renal Cancer

ESMO 2018: Tumor Molecular Characteristics in Patients with International Metastatic Renal Cell Carcinoma Database Consortium- Good and Intermediate/Poor Risk

ESMO 2018: Abundance of Riches in View of Health Care Constraints

ESMO 2018: Efficacy and Safety of Axitinib in Metastatic Papillary Renal Carcinoma: Results of GETUG, a Multicenter Phase II Trial

ESMO 2018: The Current Use of TKI in Renal Cancer

ESMO 2018: Assessment of Renal Cell Carcinoma Asymptomatic Brain Metastases Patients from GETUG-AFU 26 (NIVOREN) Trial

ESMO 2018: The Role of PD-L1 Status as A Predictor or Prognostic Marker of Clinical Outcomes in Patients Treated on CABOSUN and METEOR

ESMO 2018: Venous Thromboembolism in Cancer

ESMO 2018: Invited Discussant - IMmotion151 and ATLAS Trial Results

ESMO 2018: PD-L1 Status and Clinical Outcomes to Cabozantinib, Sunitinib and Everolimus in Patients with Metastatic Clear-Cell RCC Treated on CABOSUN and METEOR Trials

ESMO 2018: Brain Metastases Response to Nivolumab in Patients with Renal Cell Carcinoma: Prospective Analysis from the GETUG-AFU 26 (NIVOREN) Trial

1
2